CSF2 and neoplasm: Beyond live bacteria, BDVs-Neo vaccines—comprising bacterial-derived vesicles presenting neoantigens—recruit DCs via sustained GM-CSF/LPS release; when combined with anti-PD-1, they enhance tumor-infiltrating T cell activation and prevent relapse [126].